| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Review |
| Article Title |
Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: Pathophysiology, diagnosis, and emerging therapeutic strategies
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mithil Gowda Suresh, Safia Mohamed, Harinivaas S Geetha, Sushmita Prabhu, Nitin Trivedi, Zhu C Ng, Priyal D Mehta, Ajit S Brar, Aalam Sohal, Manjeet K Goyal, Juniali Hatwal and Akash Batta |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Akash Batta, Department of Cardiology, Dayanand Medical College and Hospital, Tagore Nagar, Civil Lines, Ludhiana 141001, Punjab, India. akashbatta02@gmail.com |
| Key Words |
Metabolic dysfunction-associated steatotic liver disease; Type 2 diabetes mellitus; Insulin resistance; Hepatic fibrosis; Non-invasive diagnostics; Glucagon-like peptide-1 receptor agonists; Sodium-glucose cotransporter-2 inhibitors; Personalized medicine; Fatty liver; Metabolic associated steatohepatitis |
| Core Tip |
Metabolic dysfunction-associated steatotic liver disease is highly prevalent among patients with type 2 diabetes mellitus, amplifying risks of fibrosis, cirrhosis, hepatocellular carcinoma, and cardiovascular disease. The pathogenesis reflects overlapping mechanisms of insulin resistance, dyslipidemia, inflammation, and genetic predisposition. This narrative review integrates updated evidence on epidemiology, diagnostics, and therapeutics, emphasizing the roles of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and emerging agents. A multidisciplinary, personalized approach remains essential to reduce the burden of this increasingly recognized disease spectrum. |
| Publish Date |
2026-02-06 08:43 |
| Citation |
Suresh MG, Mohamed S, Geetha HS, Prabhu S, Trivedi N, Ng ZC, Mehta PD, Brar AS, Sohal A, Goyal MK, Hatwal J, Batta A. Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: Pathophysiology, diagnosis, and emerging therapeutic strategies. World J Diabetes 2026; 17(2): 113149 |
| URL |
https://www.wjgnet.com/1948-9358/full/v17/i2/113149.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v17.i2.113149 |
